Lake Point Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lake Point Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$33K	Hold	400	–	–	0.02%	85
2022 Q1	$31K	Hold	400	–	–	0.01%	88
2021 Q4	$35K	Hold	400	–	–	0.02%	85
2021 Q3	$31K	Hold	400	–	–	0.01%	82
2021 Q2	$33K	Buy	+400	New	+$31.7K	0.02%	86
2020 Q1	$34K	Hold	400	–	–	0.03%	61
2019 Q4	$34K	Buy	+400	New	+$30.2K	0.01%	148
2019 Q2	$34K	Hold	400	–	–	0.01%	184
2019 Q1	$34K	Hold	400	–	–	0.01%	184
2018 Q4	$34K	Buy	+400	New	+$38.1K	0.01%	292

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Lake Point Wealth Management's BMRN Position: Q2 2022 in Review

Lake Point Wealth Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2022 at 400 shares worth $33K. The position accounts for 0.02% of the portfolio, ranked #85.

Lake Point Wealth Management first reported a position in BMRN in Q4 2018 and has held it in 10 quarters since. The position peaked at $35K in Q4 2021. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Lake Point Wealth Management held 400 shares of BioMarin Pharmaceuticals worth $33K as of Q2 2022.
Lake Point Wealth Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2022.
BioMarin Pharmaceuticals made up 0.02% of Lake Point Wealth Management's portfolio in Q2 2022, its #85 holding.
Lake Point Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 10 quarters since.
Lake Point Wealth Management's BioMarin Pharmaceuticals position peaked at $35K in Q4 2021.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Lake Point Wealth Management's 13F filing for Q2 2022, filed 19 Jul 2022.